Lake Bleu Capital

Lake Bleu Capital is a Hong Kong-based investment platform that focuses on the healthcare sector. The firm is dedicated to identifying and supporting innovative companies within this industry, leveraging its expertise to facilitate growth and development. Through strategic investments, Lake Bleu Capital aims to enhance the quality of healthcare services and technologies, contributing to advancements that benefit patients and healthcare providers alike.

Bin Li

Founding Partner and CEO

32 past transactions

Expedition Therapeutics

Seed Round in 2025
Expedition Therapeutics operates as an unincorporated association.

Mol Breeding

Series B in 2024
Molbreeding is a biotechnology company specializing in molecular breeding technology for both animals and plants. It offers advanced genotyping solutions aimed at enhancing breeding processes. The firm emphasizes research and development in this field, utilizing proprietary technologies such as GenoPlexs and GenoBaits. These innovations provide customers with high capture efficiency, extensive coverage, and adaptable sample options, all while maintaining cost-effective custom services. Molbreeding's focus on molecular breeding positions it as a key player in the advancement of agricultural biotechnology.

Bang Er Orthopedic

Venture Round in 2023
Zhejiang Bang Er Medical Investment Management Co., Ltd. is a prominent operator of hospitals specializing in orthopedic care and rehabilitation services, established in 2012 in Zhejiang Province, China. The company focuses on the diagnosis and treatment of various orthopedic conditions, including trauma-related injuries, hand and foot surgery, spine surgery, and joint surgery. By offering a comprehensive range of services, Bang Er aims to provide patients with the necessary care and treatment options for their orthopedic ailments, positioning itself as a key player in the healthcare sector of the Yangtze River Delta.

HC Scientific

Series B in 2023
HC Scientific (Chengdu) L.L.C., established in 2016, is a national high-tech enterprise focused on developing intelligent solutions in life technology. The company aims to empower life sciences through innovative products, including genetic testing instruments, reagents, and software, primarily used in clinical molecular diagnostics, health gene testing, and agricultural molecular breeding. HC Scientific is committed to autonomous research and development of intellectual property and is recognized for its contributions to China's new economy development initiatives. The organization employs a team of experts, including returning PhDs and professors, who have developed advanced life science technology platforms. Through its diverse product pipeline, HC Scientific streamlines complex tasks for practitioners in the life science field, thereby creating substantial value for its partners and contributing to significant national and provincial scientific and technological projects.

Center Medical

Series A in 2023
Center Medical is a cardiovascular medical services chain focused on developing a professional cardiovascular chain clinic brand.

CoJourney

Series A in 2023
CoJourney is a CDMO platform for gene therapy that combines plasmid, viral vector, and mRNA generation, analysis, and detection.

Raynovent

Series C in 2023
Raynovent is an innovative biotech company focused on researching and developing new drugs for liver and respiratory diseases. The company aims to create effective treatment therapies for patients suffering from viral and infectious illnesses in these areas. Through its expertise in pharmaceutical biotechnology consulting and technology transfer, Raynovent supports healthcare professionals in diagnosing and treating infectious diseases more effectively.

BANGBANG ROBOT

Series B in 2022
Shanghai BangBang Robot Co., Ltd. is a high-tech company established in 2016 that specializes in the research, development, production, and sales of intelligent assistant products. Based in Shanghai, the company focuses on creating robotic devices aimed at providing travel assistance. Its product offerings include rehabilitation training robots, life assistance robots, and intelligent electric scooters, all designed to enhance mobility and independence for disabled individuals. By integrating advanced technology into its products, BangBang Robot aims to enable users to travel freely and improve their quality of life.

Shenji Bio

Series A in 2022
Shenji Bio focuses on the research and development of fundamental raw materials such as nucleosides, nucleotides, diagnostic antigens, and antibodies. As a development direction, Shenji Bio provides cost-effective products and addresses clinical unmet needs. It has gradually entered the upstream core raw material fields of IVD, mRNA, CGT, and other industries, and has established a high-quality key common technology platform to provide overall solutions for the life science field's development.

Tongxin Medical Equipment

Series D in 2022
Tongxin makes magnetically-suspended artificial blood pumps which are designed to replace the human heart. They are undergoing clinical trials in China after being fast-tracked through the approval process by the National Medical Products Administration, state-run Xinhua News Agency

GenFleet Therapeutics

Series C in 2021
GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Duoning Biotech

Series C in 2021
Shanghai Duoning Biotechnology Co., Ltd. specializes in the development of serum-free, personalized, and chemically defined cell culture media for the biopharmaceutical industry. Founded in 2005 and based in Shanghai, the company offers a range of products, including basic media, feed media, and cell therapy media. Duoning Biotech is dedicated to providing tailored media development, cell culture process optimization, and commissioned formula production services, utilizing its expertise in animal cell culture concepts. The company supports the research, development, and commercialization of biologics products by delivering comprehensive solutions that encompass technical support and customized services tailored to the needs of pharmaceutical and scientific research institutions.

Singleron Biotechnologies

Series B in 2021
Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Vision X

Series B in 2021
Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.

MediTrust Health

Series C in 2021
MediTrust Health is a leading healthcare platform in China that offers a wide range of health insurance products and comprehensive medical services. The company connects pharmaceutical companies, insurers, hospitals, and patients, creating a cohesive ecosystem that benefits all stakeholders involved. By integrating high-quality medical resources with health insurance, MediTrust Health aims to deliver affordable, personalized healthcare solutions to families. In addition to its insurance offerings, the company focuses on improving the management of medical expenses and enhancing patient access to necessary services through innovative payment solutions. MediTrust Health's commitment to addressing the complexities of medical financing and providing diverse healthcare benefits positions it as a significant player in the healthcare industry.

Lupeng Pharmaceutical

Series A in 2021
Lupeng Pharmaceutical is a clinical-stage company specializing in the drug discovery and development of innovative therapies, particularly for cancer treatment. The company is actively engaged in research and development aimed at producing novel molecular drugs that address a variety of serious health conditions, including tumors and hepatitis B. Through its focus on advancing innovative treatments, Lupeng Pharmaceutical aims to provide effective solutions for combating cancer and other significant diseases.

Biocytogen

Venture Round in 2021
Biocytogen LLC is a biotechnology company based in Worcester, Massachusetts, that specializes in developing gene-targeted animal models for life science research. Founded in 2008, the company offers a range of services, including customized and off-the-shelf mouse models, phenotype analysis, and advanced gene-editing techniques. Its products encompass various types of mice, such as knockin and knockout models, as well as humanized mice, catering to diverse research areas including immunology, neurology, cancer, and infectious diseases. Biocytogen also operates a state-of-the-art animal facility to support its integrated platform for efficient antibody drug discovery and validation. The company collaborates with leading pharmaceutical and biotechnology firms to enhance preclinical research and development processes in the biomedical field.

Valgen Medtech

Series B in 2021
Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.

WeMed Medical

Series D in 2021
WeMed Medical is a developer of digital angiography machines designed for use in the clinical fields of radiology and cardiology. The company focuses on arranging department operations and conducting training for medical professionals to ensure effective utilization of its products. Additionally, WeMed Medical is involved in the international strategic planning of product research and development, enabling the continuous optimization and upgrading of its offerings. This comprehensive approach allows the company to meet the evolving needs of healthcare providers while enhancing patient care.

AffaMed Therapeutics

Series B in 2021
AffaMed Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products. The company focuses on accelerating the clinical development of new therapies aimed at addressing significant unmet medical needs, particularly in the fields of ophthalmology, neurology, and psychiatry. By targeting these critical areas, AffaMed strives to create impactful solutions that improve the lives of patients globally.

Brii Biosciences

Series C in 2021
Brii Biosciences Limited is a biotechnology company focused on the research, development, and commercialization of innovative medicines for chronic and infectious diseases, including hepatitis B virus (HBV), human immunodeficiency virus (HIV), and multi-drug resistant infections. Founded in 2018, the company is headquartered in Durham, North Carolina, with additional offices in Shanghai, Beijing, and San Francisco. Brii Biosciences aims to enhance healthcare outcomes for patients in China by leveraging advanced technology and data. The company has established strategic partnerships with organizations such as AliHealth and Vir to further its mission. With a robust pipeline consisting of over 10 product candidates, Brii Biosciences is dedicated to addressing significant public health challenges both in China and globally, focusing on delivering better treatments and cures for life-threatening diseases.

Exegenesis Bio

Series B in 2021
Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Abbisko Therapeutics

Series D in 2021
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and manufacturing of innovative immuno-oncology therapies. Founded in 2016 by a team of experienced professionals from leading pharmaceutical companies, Abbisko is dedicated to developing small molecule inhibitors, including ABSK011 and ABSK021, for the treatment of hepatocellular carcinoma, as well as CSF1R for solid tumors. In addition to oncology, the company is engaged in developing therapeutics for various conditions, including cancer, liver diseases, diabetes, metabolic disorders, viral infections, and central nervous system diseases.

Broncus Medical

Series C in 2020
Broncus Medical is a medical technology company specializing in the development of minimally-invasive devices for treating lung diseases, including emphysema and lung cancer. Based in Mountain View, California, with an international presence in Nyon, Switzerland, Broncus is focused on addressing significant unmet medical needs in interventional pulmonology. The company is exploring its Exhale product line, which features a patented treatment method known as Airway Bypass, aimed at providing a minimally-invasive solution for patients suffering from homogeneous emphysema. Broncus is currently conducting the pivotal EASE Trial, enrolling patients worldwide to evaluate the efficacy of this treatment in severe cases of the disease. Additionally, Broncus offers a range of innovative products designed to enhance diagnostic and therapeutic outcomes in lung care, including the Archimedes System, LungPoint, and InterVapor System.

Ruipeng Pet Healthcare

Venture Round in 2020
Ruipeng Pet Hospital, located in Shenzhen, specializes in a comprehensive range of pet care services. The hospital provides medical and beauty care for pets, including healthcare, foster care, bathing, SPA treatments, grooming, food, and entertainment. By offering both digital and clinical services, Ruipeng aims to ensure that pet owners can access high-quality care for their animals efficiently. The organization also includes online shopping options to further support pet owners in meeting their pets' needs.

I-Mab Biopharma

Post in 2020
I-Mab Biopharma (Shanghai) Co., Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, with additional offices in Beijing and Rockville, Maryland. Founded in 2016, the company focuses on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the fields of immuno-oncology and immuno-inflammation. I-Mab's diverse drug pipeline targets various therapeutic areas, including multiple myeloma, autoimmune diseases, pediatric growth hormone deficiency, and several cancer indications such as head and neck cancer. Key candidates in its portfolio include Uliledlimab, an antibody for solid tumors, along with Ragistomig and Givastomig, highlighting the company's commitment to developing transformative therapies for patients.

MicroPort CardioFlow

Private Equity Round in 2020
Shanghai MicroPort CardioFlow Medtech Co., Ltd., established in 2015, is a medical device company specializing in advanced minimally invasive therapies for structural heart diseases. As a subsidiary of MicroPort Scientific Corporation, it focuses on the research, development, and commercialization of innovative solutions for valvular heart diseases. The company's product portfolio includes VitaFlow, VitaFlow Liberty, Alwide Plus, and a range of transcatheter aortic valve implantation (TAVI), transcatheter mitral valve (TMV), and surgical valve products, along with procedural accessories. Primarily operating in China, MicroPort CardioFlow emphasizes the importance of improving patient quality of life through reliable and affordable healthcare solutions while maintaining a global vision for its products and services.

Mabworks

Series C in 2020
Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.

RemeGen

Venture Round in 2020
RemeGen, Ltd. is a biopharmaceutical company based in Yantai, Shandong Province, China, focused on addressing unmet medical needs for patients with life-threatening conditions. The company specializes in the research, development, manufacturing, and commercialization of innovative biologics, particularly monoclonal antibodies and antibody-drug conjugates. RemeGen's leading products include Telitacicept, aimed at treating systemic lupus erythematosus, and Disitamab Vedotin, designed for various cancers. The company’s therapeutic offerings target significant health issues, including autoimmune diseases, oncology, and ophthalmology. With operations in both China and the United States, RemeGen primarily generates its revenue from the Chinese market.

Rongchang Pharmaceutical

Series A in 2020
Yantai Rongchang Pharmaceutical Co., Ltd. is a pharmaceutical company based in Yantai, China, founded in 1993. The company engages in the research and development, production, and distribution of modern Chinese medicine and biological drugs. Over the years, Rongchang Pharmaceutical has evolved into a comprehensive enterprise that combines various aspects of the pharmaceutical industry, focusing on innovation and the development of effective healthcare solutions.

Akeso Biopharma

Series D in 2019
Akeso Biopharma, Inc. is a contract research organization based in Zhongshan, China, specializing in the discovery and development of antibody and protein drugs. Established in 2012, the company offers a range of integrated services to both domestic and international pharmaceutical firms, including protein expression and purification, antibody generation, assay development, humanization, and affinity maturation. Akeso has developed a comprehensive biopharmaceutical research and development platform, focusing on therapeutic areas such as cancer, autoimmune diseases, inflammation, and cardiovascular diseases. With a robust pipeline of over 30 drug candidates, 17 of which are in clinical stages, Akeso is recognized for its innovative approaches, including the development of first-in-class bi-specific antibody drugs. The company collaborates with various pharmaceutical enterprises to advance the joint development of new drugs, positioning itself as a leader in the biopharmaceutical industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.